Mavrilimumab, a fully human granulocyte ‐macrophage colony‐stimulating factor receptor α monoclonal antibody: long‐term safety and efficacy in patients with rheumatoid arthritis

ConclusionMavrilimumab long‐term treatment maintained response and was well‐tolerated with no TEAE incidence increase. Safety data were comparable with both phase IIb qualifying studies.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatism - January 23, 2018 Category: Rheumatology Authors: Gerd R Burmester, Iain B McInnes, Joel M Kremer, Pedro Miranda, Ji ří Vencovský, Alex Godwood, Marius Albulescu, M Alex Michaels, Xiang Guo, David Close, Michael Weinblatt Tags: Full Length Source Type: research